[A therapeutic Trojan horse: intracellular antibodies].
Intracellular immunization is a novel therapeutic approach based on intracellular expression of recombinant antibody fragments, either Fab or single chain Fv (scFv generated by the assembly of the VH with the VL region), targeted to the desired cell compartment (cytosol, nucleus, endoplasmic reticulum ...) using appropriate targeting sequences. Due to their exquisite specificity, these intracellular antibodies can be used to neutralize or modulate the functional activity of the target molecule. Intracellular immunization strategies currently under investigation in the field of oncology are directed against mutated oncogenic molecules such as ErbB-2, p21ras, and p53, as well as against apoptosis-inhibiting molecules such as Bcl-2. The first Phase I clinical trials on intracellular immunization are under way in the United States.
Teillaud
J L
JL
Laboratoire de Biotechnologie des Anticorps, Institut Curie, Paris, France.
D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000918:Antibody Specificity; D002451:Cell Compartmentation; D006801:Humans; D007114:Immunization; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D008969:Molecular Sequence Data; D011994:Recombinant Proteins / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D011994:Recombinant Proteins